Study group | Age/gender/study eye | Dose (cells) | Cell viability (%) | Eye | IOL | BCVA (logMAR) | Visual field (degrees) | ERG | VEP | Â | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  |  | S | N | I | T |  | Amplitude (mV) | Latency (ms) |
1 | 38/M/OD | 1 × 106 | 86.00 | OD OS | No No | 2.00 2.00 | 10 10 | 10 10 | 10 10 | 10 10 | NR NR | 5.465 5.985 | N/A |
1 | 58/M/OD | 1 × 106 | 87.5 | OD OS | Yes Yes | 1.40 1.51 | 10 10 | 10 10 | 10 10 | 10 10 | NR NR | 6.357 1.950 | 98 106 |
1 | 58/M/OD | 1 × 106 | 95.70 | OD OS | No No | 1.08 1.30 | 10 10 | 10 11 | 10 10 | 12 10 | NR NR | 2.995 5.725 | 134 134 |
1 | 56/F/OD | 1 × 106 | 93.00 | OD OS | No No | 2.30 2.30 | 10 25 | 10 10 | 15 40 | 10 24 | NR NR | 5.075 6.505 | 152 145 |
1 | 42/M/OD | 1 × 106 | 94.00 | OD OS | No No | 2.30 2.30 | 10 10 | 10 10 | 10 10 | 10 10 | NR NR | 4.615 5.550 | 105 98 |
1 | 46/F/OD | 1 × 106 | 94.05 | OD OS | Yes Yes | 2.30 2.30 | N/A | N/A | N/A | N/A | NR NR | 5.335 5.465 | 123 100 |
1 | 35/F/OD | 1 × 106 | 86.60 | OD OS | No No | 1.47 1.36 | 45 55 | 55 50 | 70 60 | 75 72 | NR NR | 14.84 11.72 | 120 119 |
2 | 61/M/OD | 5 × 106 | 96.00 | OD OS | Yes No | 1.22 1.08 | 10 10 | 10 10 | 10 10 | 10 10 | NR NR | 4.615 3.645 | 114 105 |
2 | 42/M/OD | 5 × 106 | 96.73 | OD OS | No No | 2.30 2.30 | N/A | N/A | N/A | N/A | NR NR | 4.680 3.900 | 106 107 |
2 | 48/M/OD | 5 × 106 | 93.75 | OD OS | No No | 2.70 2.70 | N/A | N/A | N/A | N/A | NR NR | 3.380 2.990 | 135 121 |
3 | 45/F/OD | 1 × 107 | 93.07 | OD OS | Yes Yes | 2.30 2.30 | N/A | N/A | N/A | N/A | NR NR | 3.510 5.335 | 131 135 |
3 | 37/M/OD | 1 × 107 | 92.58 | OD OS | No No | 2.70 2.30 | N/A | N/A | N/A | N/A | NR NR | 2.470 4.290 | 130 128 |
3 | 49/M/OD | 1 × 107 | 89.14 | OD OS | Yes Yes | 1.34 2.30 | N/A | N/A | N/A | N/A | NR NR | N/A | N/A |
3 | 32/F/OD | 1 × 107 | 91.60 | OD OS | No No | 2.00 2.00 | 10 10 | 10 10 | 10 10 | 10 10 | NR NR | N/A | N/A |